Loading company…
Florham Park-based developer of treatments for acid-related gastrointestinal disorders, including the prescription drug VOQUEZNA.
Founded in 2018 and headquartered in Florham Park, US, Phathom Pharmaceuticals develops treatments for gastrointestinal diseases, with a focus on acid-related disorders. Its flagship product, VOQUEZNA (vonoprazan), is a prescription medicine for non-erosive and erosive gastroesophageal reflux disease in adults. The company has raised a total of USD 150.33 mn, including a Private Placement/Follow on in May 2023, and reported revenue of USD 682,000 in its most recent year. CEO David Socks leads the company, and its stage is listed as Series C.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in